Literature DB >> 16586052

[Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions].

D Weckermann1, M Hamm, R Dorn, T Wagner, F Wawroschek, R Harzmann.   

Abstract

There is no consensus on which prostate cancer patients should undergo lymph node removal and which lymph nodes should be included. Therefore, most clinicians rely on nomograms and dispense with lymph node dissection in patients with low-risk disease. Meanwhile, there are some studies which prove that there are also lymph node metastases in patients with low-risk prostate cancer and that lymph node metastases are predominantly localized outside the region of standard lymphadenectomy. In more than 800 men we could show that lymph node metastases were found more often than shown in the Partin tables. These lymph node metastases were detected by sentinel lymph node dissection outside the region of standard and extended lymphadenectomy. Because of insufficient preoperative diagnostics it is unclear which patients have positive lymph nodes. Therefore, it is useful to perform lymph node dissection in every patient. Men with positive nodes could have a better prognosis, when sentinel and extended lymph node dissection are performed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16586052     DOI: 10.1007/s00120-006-1030-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

1.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

2.  Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of <10 ng/ml undergoing radical prostatectomy for prostate cancer?

Authors:  Fiona C Burkhard; Martin Schumacher; George N Thalmann; Urs E Studer
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

3.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.

Authors:  A W Partin; L A Mangold; D M Lamm; P C Walsh; J I Epstein; J D Pearson
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

4.  The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification.

Authors:  F Wawroschek; H Vogt; D Weckermann; T Wagner; R Harzmann
Journal:  Eur Urol       Date:  1999-12       Impact factor: 20.096

5.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?

Authors:  Dorothea Weckermann; Friedhelm Wawroschek; Rolf Harzmann
Journal:  Eur Urol       Date:  2005-01       Impact factor: 20.096

7.  Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection.

Authors:  Stephan Jeschke; Thiagarajan Nambirajan; Karl Leeb; Josef Ziegerhofer; Wolfgang Sega; Günter Janetschek
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

8.  Is a limited lymph node dissection an adequate staging procedure for prostate cancer?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

9.  Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases.

Authors:  Friedhelm Wawroschek; Harry Vogt; Hermann Wengenmair; Dorothea Weckermann; Michael Hamm; Mathias Keil; Gerhard Graf; Peter Heidenreich; Rolf Harzmann
Journal:  Urol Int       Date:  2003       Impact factor: 2.089

10.  Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer.

Authors:  Mohamad E Allaf; Ganesh S Palapattu; Bruce J Trock; H Ballentine Carter; Patrick C Walsh
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

View more
  4 in total

1.  Preclinical evaluation of robotic-assisted sentinel lymph node fluorescence imaging.

Authors:  Michael A Liss; Salman Farshchi-Heydari; Zhengtao Qin; Sean A Hickey; David J Hall; Christopher J Kane; David R Vera
Journal:  J Nucl Med       Date:  2014-07-14       Impact factor: 10.057

Review 2.  Sentinel node biopsy and lymphatic mapping in penile and prostate cancer.

Authors:  H G van der Poel; P Meershoek; N Grivas; G KleinJan; F W B van Leeuwen; S Horenblas
Journal:  Urologe A       Date:  2017-01       Impact factor: 0.639

Review 3.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

4.  Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?

Authors:  Matthias Guckenberger; Kurt Baier; Anne Richter; Dirk Vordermark; Michael Flentje
Journal:  Radiat Oncol       Date:  2008-01-11       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.